Albion Capital Fund Managers
Dr Andrew Elder
Andrew initially practised as a surgeon for six years, specialising in neurosurgery, before joining the Boston Consulting Group (BCG) as a consultant in 2001. Whilst at BCG he specialised in healthcare strategy, gaining experience with many large, global clients across the full spectrum of healthcare including biotechnology, pharmaceuticals, service and care providers, software and telecommunications. Andrew now focuses on medical technologies, digital health and technology-enabled services to the life-science sector, and has served on the boards of companies ranging from diagnostics, imaging and software to pharmaceuticals and biomarkers. He has an MA plus Bachelors of Medicine and Surgery from Cambridge University and is a Fellow of the Royal College of Surgeons (England). He joined Albion Capital in 2005 and became deputy managing partner in 2019.
Dr Christoph Ruedig
Christoph focuses on investments in healthcare and renewables. He initially practised as a radiologist, before spending 3 years at Bain & Company. In 2006, he joined 3i working for their Healthcare Venture Capital after which he worked for General Electric's healthcare division, where he was responsible for mergers and acquisitions in the medical technology and healthcare IT sectors. He holds a degree in medicine from Ludwig-Maximilians University, Munich and an MBA from INSEAD.
Ed has been investing with AlbionVC since 2004 and leads the technology investments for the VCTs and UCL Technology Fund. Prior to Albion, Ed worked at ING Barings advising UK public companies on M&A, IPOs and fundraisings in the tech, healthcare and financial services sector. Ed graduated from UCL with a 1st in Philosophy.
David manages the physical science side of the UCL Technology Fund which includes investments across Cybersecurity, Edtech, Medtech and Artificial Intelligence. Before joining Albion, David was an investment manager with Spark Impact, a subsidiary of Spark Ventures, investing across Medtech, Digital Health and Consumer Healthcare. He started his career at Detica before moving to China to work in a FMCG start-up. David holds a Masters’ degree in Natural Science (Mathematics and Chemistry). Outside of the office David enjoys playing Jianzi, optimising his bbq smoking technique and is an active member of his local church.
Dr Simon Goldman
Simon completed his PhD (and postdoc) in neuroscience at the University of Cambridge, prior to which he worked for seven-and-a-half years at Goldman Sachs JBWere in Melbourne, predominantly on the Healthcare/Biotech and Portfolio Strategy Research teams. He worked in several roles across the UK and Australian biotech startup sectors before joining Albion in 2015 to manage the life-sciences side of the UCL Technology Fund. Simon is a dedicated (and somewhat evangelical) rock-climber and alpine mountaineer, and an active member of both the London and Melbourne Symphony Orchestra Choruses.
Dr Tanel Ozdemir
Tanel joined Albion in 2018 having previously been an intern with the investment team in 2016. Tanel completed his PhD and postdoctoral research at UCL where his work was focused on developing synthetic biological tools for microbiome engineering. He also holds an MSc in Nanotechnology and Regenerative Medicine from UCL and a BSc in Human Biology from King’s College London.
UCLB Management Team
Dr Anne Lane
Anne has a PhD in medicine from UCL and an Executive MBA from Molson Business School, Montreal. After research at UCL and Harvard Medical School, Anne worked for RTP Pharma Inc in Montreal, out-licensing and preparing valuations of the company’s portfolio for public listing. Anne joined UCL Ventures in 2000 and acted as consultant for the National Transfer Centre in the US. Previously Executive Director of UCLB, Anne was appointed CEO of the company in 2019. Anne acts as Director and interim CEO on several of UCLB’s spinout companies and oversees the company’s licensing activity. Anne is also a member of the Licensing Executives Society (LES) and is on the committee for the Intellectual Property Lawyers Organisation (TIPLO).
Dr Richard Fagan
Rick is a cell and molecular biologist by training, gaining his PhD at McGill University, Canada. This was followed by a postdoctorate at the Imperial Cancer Research Fund, London, and then the National Institute for Medical Research. He left to join AstraZeneca as a team leader in the Department of Target Discovery, then worked for SanofiAventis as a Senior Team leader. In 2001 he left SanofiAventis and joined Impharmatica as Associate Director Target Discovery and worked very closely with the business development team. In 2006 he joined UCLB as Assistant Director BioPharm, becoming Director in 2007.
Dr Steven Schooling
Steven is the Director of Physical Sciences, Engineering, Built Environment & Social Sciences at UCLB. Steven brings extensive experience of licensing and spinout company creation to the UCLB team across areas ranging from ICT and petrochemicals through to medical devices and imaging. He is an engineer by training with a PhD in Process Control Engineering from Manchester Metropolitan University, which is complemented by industrial experience in the newspaper and process control industries and an Executive MBA from Manchester Business School. Steven is currently the Director of six UCL spinout companies and represents UCL’s interests in an IT-focused seed stage investment fund.
UCLTF Investment Committee
Dr Andy Richards CBE
Andy has an established track record in founding and scaling up innovative Biotech and Healthtech companies in the UK. He is currently Chairman of Arecor, Congenica, Abcodia, and the Babraham Research Campus and is a Director of Ieso Digital Health, Silence Therapeutics plc, Cancer Research Technology (commercial arm of CR-UK) and Cambridge University Hospitals NHS Foundation Trust. In addition to the UCL Technology Fund, he is an advisor to Cambridge Innovation Capital. His early career spanned positions with ICI (now AstraZeneca) and PA Technology, and he was a founder and executive director of Chiroscience plc. Since 1999 he has founded, invested in and helped to scale more than 25 innovative ventures including companies such as Vectura, Arakis, Cambridge Biotechnology Ltd and Geneservice. Andy is also a founder member of the Cambridge Angels and a trustee of the British Science Association.
Andy's focus is investing in and working with tech startups, supplemented by teaching at business school. He is the former CEO of Priceline's non US operations, co-founder of Active Hotels (merged with bookings.org to form what is now Booking.com), former chairman of Toptable (now part of Priceline) and is involved in many other projects.
Dr Eliot Forster
Dr Eliot Forster is the current CEO of F-star and most recently CEO of Immunocore. He has more than 25 years of experience in the pharmaceutical and biotechnology industry. Dr Forster previously served as Chief Executive Officer of Creabilis since 2010 and prior to that role was Chief Executive Officer of US biotechnology company, Solace Pharmaceuticals Inc. His other previous roles include Head of EU Development and Operations for the EU and Asia at Pfizer, where he was responsible for drug development activities across multiple geographies and brought several drugs to market, and Clinical Research Manager at GlaxoSmithKline. Dr Forster is currently Chairman of the MedCity project that aims to grow a world-leading life sciences cluster in the south east of England. He holds a PhD in neurophysiology from Liverpool University and an MBA from Henley Management College.
Dr Robin Brown
Dr Robin Brown is the Chairman of Medicines Discovery Catapult having most recently been CEO of KWS BioTest, prior to that Robin spent eight years as a venture partner at Advent Healthcare Ventures and was responsible for a number of companies within the investment portfolio. He was also the Chief Scientific Officer of Devgen and Galapagos (EBR:DEVG, EBR:GLPG), both of which are now publically listed companies. Robin spent nine years at GSK, latterly as Head of Cell Biology and as an academic gained his PhD in the laboratory of Prof Alan Hall. He undertook postdoctoral work in the United States (Harvard) and London (Ludwig Institute).